

High-Throughput Proteomics Quantification Enabled by Fast LC Separation and Advanced PRM Acquisition

Sebastien Gallien^{1,2}, Aaron Gajadhar³, Bhavin Patel⁴, Tabiwang Arrey⁵, Dave Sarracino², Yue Xuan^{2,5}, Emily Chen²

¹Thermo Fisher Scientific, Paris, France; ²Thermo Fisher Scientific, Precision Medicine Science Center, Cambridge, MA; ³Thermo Fisher Scientific, San Jose, CA; ⁴Thermo Fisher Scientific, Rockford, IL; ⁵Thermo Fisher Scientific, Bremen, Germany

ABSTRACT

Purpose: High-throughput LC-PRM set-ups were developed, based on fast LC separations and advanced PRM acquisition schemes, to support proteomics studies. They were applied to the monitoring of the main protein components of AKT/mTOR signaling pathway enriched or not through multiplex immunoprecipitation (targeting their "total" or "phosphorylated" forms). A novel IS-PRM method variant was also developed to further increase the analytical throughput and open the way to fast broad-coverage/multi-pathway monitoring studies.

Methods: The analyses were performed on a Thermo Scientific™ Q Exactive™ HF-X hybrid quadrupole-Orbitrap™ mass spectrometer and a Thermo Scientific™ Q Exactive™ HF hybrid quadrupole-Orbitrap mass spectrometer operated with several PRM-based acquisition schemes (using instrument programming interface in some cases). Chromatographic separations were carried out using an Evosep One system and a Thermo Scientific™ UltiMate™ 3000 RSLC system equipped for capillary flow. Various gradient lengths and MS acquisition parameter settings were employed to analyze samples of high complexity, e.g., digests of human cell lines, and samples of low complexity obtained through multiplexed immunoprecipitation targeting proteins of AKT/mTOR pathway.

Results: The developed set-ups exhibited the ability to quantify with high sensitivity several dozens of endogenous peptides in one hundred samples within one day under high efficiency acquisition modes. Advanced PRM methods allowed further increases in analytical throughput without compromising the quality of quantification data when combined with multiplexed immunoprecipitation, and minor sensitivity decrease without enrichment. The novel IS-PRM method variant, relying on multiplexed isolation/fragmentation and single MS/MS spectrum acquisition, turned out to be a promising option for broad-coverage/multi-pathway monitoring studies while maintaining acceptable quantification performance.

INTRODUCTION

Targeted analyses based on HRAM parallel reaction monitoring (PRM) measurements have opened new opportunities in quantitative proteomics. The PRM technique has delivered a significant increase in selectivity of measurements, allowing more sensitive endogenous peptide quantification in complex samples. Refined acquisition methods, e.g., internal standard triggered-PRM (IS-PRM)¹, have enabled larger-scale experiments while still providing exquisite data quality. Here the potential of PRM combined with fast capillary-flow LC separation has been explored to accelerate the throughput of targeted analyses.

MATERIALS AND METHODS

Sample Preparation

Cell Culture: HCT116 cells were grown in McCoy's 5A Media with 10% FBS/1xPenStrep to ~70-80% confluency. HCT116 cells were serum starved in 0.1% charcoal stripped FBS for 24 hours prior to the following treatments: untreated, stimulated (15 min hIGF-1 (100ng/mL; Cell Signaling Technology PNH9175F)). Subsequent to treatments, cells were lysed with IP-Lysis buffer (Thermo Fisher Scientific PN#977798) supplemented with 1X HALT Protease and Phosphatase inhibitor cocktail (Thermo Fisher Scientific PN#78440). Protein concentration of lysates was determined with BCA assay. Multiplex Immunoprecipitation (mIP): The Thermo Scientific™ Pierce™ MS-Compatible Magnetic IP Kit, Protein A/G (Thermo Fisher Scientific PN#90409) was used to screen and validate antibodies for 13 total and 12 phosphorylated AKT/mTOR pathway targets from 500µg cell lysate. Validated antibodies were biotinylated with the Thermo Scientific™ Pierce™ Antibody Biotinylation Kit for IP (Thermo Fisher Scientific PN#90407). The Thermo Scientific™ Pierce™ MS-Compatible Magnetic IP Kit, Streptavidin (Thermo Fisher Scientific PN#90408) was used to multiplex IPs for target enrichment. IP samples were processed by an in-solution digestion method in which IP eluates were reconstituted with 6M Urea, 50mM TEAB (pH 8.5) followed by reduction, alkylation and trypsin (Thermo Fisher Scientific PN#90057) digestion overnight at 37°C. The digested samples were acidified with TFA. MS sample preparation: A set of 32 high-purity Pierce™ stable isotopically labeled (SIL) peptides corresponding to 13 proteins from AKT/mTOR pathway was spiked at 20 fmol in 500 ng of HCT116, i) after mIP, or ii) with no enrichment. For the preparation of the dilution series solutions in "low complexity" matrix, the set of 32 SIL peptides was spiked in various calibrated amounts (7 points from 50 amol to 200 fmol, and one matrix blank) in 1 µmol of a 6-protein mix digest (Thermo Fisher Scientific PN#88342) supplemented with 20 fmol of synthetic unlabeled forms of the peptides. For the preparation of the dilution series solutions in "high" complexity matrix, the set of 32 SIL peptides was spiked in various calibrated amounts (7 points from 50 amol to 200 fmol, and one matrix blank) in 500 ng of a HeLa digest (Thermo Fisher Scientific PN#88329) supplemented with 20 fmol of synthetic unlabeled forms of the peptides. A set of 186 standard-purity SIL peptides (Pierce, Rockford, IL; JPT, Peptide Technologies, Berlin, Germany) corresponding to 111 signaling pathway proteins was spiked at 150 fmol (nominal amount) in 1 µg of HeLa digest and used to follow MAPK, Wnt, RAS, ErbB, and AKT/mTOR pathways in the multi-pathway monitoring experiment. All samples were supplemented with 30 fmol of a mixture of PRTC peptides (Thermo Fisher Scientific, PN#88321).

LC-MS/MS Analysis

For single-signaling pathway monitoring experiments, chromatographic separations were performed on an Evosep One system (Evosep, Odense, Denmark) equipped with Evosep C₁₈ EvoTips and C₁₈ analytical columns (3 µm, 0.1 x 80 mm operated at 1 or 1.2 µL/min, or 3 µm, 0.15 x 50 mm operated at 1.5 µL/min). For the multi-pathway monitoring experiment, chromatographic separations were performed on an UltiMate 3000 RSLC system in capillary flow mode equipped with C₁₈ trap cartridges (5 µm, 0.3 x 5 mm operated at 100 µL/min) and analytical column (2 µm, 0.15 x 150 mm operated at 3 µL/min). The various gradient lengths used are detailed in relevant Figures. Evosep One and Ultimate 3000 RSLC systems were coupled to Q Exactive HF-X MS and Q Exactive HF quadrupole-Orbitrap MS instruments, respectively. Mass spectrometers were operated with several PRM-based acquisition schemes including dRT-PRM², IS-PRM¹ (using the instrument application programming interface, iAPI). Under its main implementation ("sequential"), the IS-PRM technique alternated between i) a "watch mode", in which internal standards (IS) were continuously measured in their (dynamically corrected) elution time monitoring windows at fast scanning rates, and ii) a "quantitative mode" (triggered by the real-time detection of the IS by means of spectral matching), which measured the corresponding pairs of IS and endogenous peptides serially over their elution profile, using optimized acquisition parameters (Figures 1 and 2). For all PRM, dRT-PRM, and IS-PRM (Quant. mode) experiments on Q Exactive HF-X instrument, PRM scans employed an Orbitrap resolution of 60,000 (at m/z 200) and maximum fill times of 116 ms. The watch mode of IS-PRM employed an Orbitrap resolution of 7,500 (at m/z 200) and maximum fill times of 10 ms. A variant of the IS-PRM method, relying on the simultaneous measurement of SIL and endogenous peptides by "multiplex" acquisition of their fragment ions in a single MS/MS spectrum in Quant. mode, was developed and tested (Figures 1 and 2) to further increase analytical throughput.

Figure 1. Peptide monitoring strategies in PRM and advanced PRM methods.






Figure 2. "Sequential" and "Multiplex" implementation of the quantitative mode of IS-PRM.



Considerations for High-Throughput LC-PRM Analysis

Figure 3. Determination of the chromatographic properties of Evosep system operated at throughputs of 60-, 100-, and 200-samples analyzed/day, based on LC-MS analysis of 15 PRTC peptides.



The chromatographic properties of the Evosep system were determined from LC-MS analyses of 15 PRTC peptides, covering the typical elution range of tryptic peptides (Figure 3). Three gradient lengths (from 5 to 21 min) were evaluated on two different column formats, enabling throughputs of 60-, 100-, and 200-samples analyzed per day, owing to minimized overhead in duty cycle (≤ 3 min). Based on the total elution window and peptide chromatographic peak widths associated with each set-up, the number of peptides that can be included in conventional PRM, dRT-PRM and IS-PRM experiments were predicted (Table 1). Predictions were performed for both ideal situation under which the elution times of the peptides are evenly distributed over the LC separation, and more common situation under which peptide elution times are compressed into chromatographic sub-ranges. As compared with conventional PRM, the higher acquisition efficiency of dRT-PRM, and especially IS-PRM, enabled significant increase in experiment scale at constant analytical throughput.

Table 1. Estimation of the scale achievable by PRM, dRT-PRM and IS-PRM analyses.

Throughput	Method MS	MS parameters ^a (Res.-Fill Time)	Monitoring window ^b	Nb targets (pairs HL peptides) – Theoretical ^{c,d}	Nb targets (pairs HL peptides) – Typical (Z-3) ^d
60 samples/day	PRM	60k - 116ms	0.9	98	32-48
60 samples/day	dRT-PRM	60k - 116ms	0.45	188	62-93
60 samples/day	IS-PRM	60k - 116ms ^e	0.45	391	130-195
100 samples/day	IS-PRM	60k - 116ms	0.66	37	12-18
100 samples/day	dRT-PRM	60k - 116ms	0.33	70	23-34
100 samples/day	IS-PRM	60k - 116ms ^e	0.33	149	49-74
200 samples/day	PRM	60k - 116ms	0.5	15	5-7
200 samples/day	dRT-PRM	60k - 116ms	0.25	28	9-13
200 samples/day	IS-PRM	60k - 116ms ^e	0.25	62	20-30

^a For Q Exactive HF-X MS; ^b Estimated as 5-6 and 2-3 x peak width in conventional PRM and dRT-PRM/IS-PRM analyses; ^c For an even distribution of peptide elution times over the LC separation; ^d For a sampling rate of 6 data points/peak; ^e In QUANT mode

AKT/mTOR Pathway Monitoring by Fast LC-PRM

Fast LC-PRM methods were applied to the monitoring of a single signaling pathway. A total of 13 proteins were defined as main components of AKT/mTOR pathway (Figure 4, upper right panel). Two to four peptides were selected as surrogate of each protein. The Evosep LC method, allowing 60 samples/day analytical throughput, was selected as suited to PRM analysis of the 32 pairs of SIL and endogenous peptides corresponding to the target proteins (Table 1 and Figure 4, upper left panel). PRM assays were developed by measuring the dilution series of the 32 SIL peptides in "low" and "high" complexity matrices (6-protein mix and HeLa digests, respectively) supplemented with constant amount of corresponding synthetic unlabeled peptides (Figure 4, lower left panel). Peptide assays characteristics (i.e., LOD, LOQ, and linearity range) were determined, as illustrated with the LOQs in low complexity matrix presented in Figure 4 (lower right panel).

Figure 4. Establishment and characterization of conventional PRM assays for AKT/mTOR surrogate peptides.





Figure 5. PRM analyses of the surrogate peptides of AKT/mTOR pathway "phospho"-proteins immunoprecipitated from untreated and hIGF-1 stimulated HCT116 digest.





Figure 5. PRM analyses of the surrogate peptides of AKT/mTOR pathway "total"-proteins immunoprecipitated from untreated and hIGF-1 stimulated HCT116 digest.



The PRM assays developed for the quantification of AKT/mTOR surrogate peptides were applied to untreated and hIGF-1 stimulated HCT116 digest prepared i) by multiplex immunoprecipitation targeting phosphoproteins of the pathway (Figure 4, ii) by multiplex immunoprecipitation targeting "total" proteins of the pathway (Figure 5, upper panel), and iii) without enrichment (Figure 5, lower panel). The overall protein digest amount injected on the LC column for conventional PRM analyses was 0.5 µg for non-enriched samples and samples prepared by multiplex immunoprecipitation, as illustrated with the total ion chromatograms displayed in left panels of Figures 4 and 5. Peptide surrogates were quantified based on the measurements of pairs of SIL and endogenous in triplicated LC-PRM analyses. While hIGF-1 stimulation did not induce changes in total protein abundances, it modified the activation status of most of them, as illustrated by the significant increase in the peptide abundance of phosphoproteins (especially IGF1R, INSR, and AKT proteins). The multiplexed immunoprecipitation steps allowed differentiated quantification of phospho- and total-proteins but also quantification of additional peptides, benefiting from the decrease in sample complexity and the enrichment of targets.

Throughput Capabilities of Advanced PRM Methods

AKT/mTOR pathway monitoring experiments were repeated using advanced PRM methods. The higher efficiency of dRT-PRM and IS-PRM acquisition schemes enabled the selection of faster Evosep LC methods (Table 1), allowing 100- and 200-samples/day analytical throughput, respectively, while keeping same PRM scans settings (quant. mode for IS-PRM). The analyses exhibited sampling rates similar to those of conventional PRM analyses using "60 samples/day" LC method (Figure 6). The compressed gradients used with advanced PRM methods did not affect the sensitivity of measurements in low complexity matrix (e.g., multiplexed immunoprecipitated samples) and only moderately compromised it in a more complex matrix (Figures 7 and 8).

Figure 6. Analyses of the 32 pairs of SIL and endogenous peptides surrogate of the 13 AKT/mTOR proteins.




Figure 7. Limits of detection of peptides from dilution series analyses in "low" and "high" complexity matrices.





Figure 8. Success rate and reproducibility of quantification of the 32 endogenous peptides surrogate of the 13 AKT/mTOR proteins by conventional PRM, dRT-PRM, and IS-PRM analyses across mIP / no IP experiments.



Towards Higher Throughput PRM Acquisition Variant

A novel IS-PRM method variant, relying on multiplexed isolation/fragmentation of pairs of SIL and endogenous peptide precursor ions and single MS/MS spectrum acquisition, was explored. It was applied to the measurement of the dilution series of the 32 SIL peptides surrogate of the 13 AKT/mTOR proteins in low complexity matrix using "200 samples/day" LC set-up. The method exhibited good quantification accuracy (Figure 9) while enabling a 3-4 fold increase in experiment scale, as compared with sequential IS-PRM analysis. This was illustrated by the analyses of 186 pairs of SIL and endogenous peptides using "100 samples/day" LC method with satisfying sampling rate (Figure 10).

Figure 9. Accuracy of single-scan IS-PRM msx quantification of 13 AKT/mTOR proteins (32 SIL) in each dilution series solution using "200 samples/day" LC method. Quantification process relied on single-point calibration.





Figure 10. Single-scan IS-PRM msx analysis of 186 pairs of SIL/ENDO peptides (corresponding to 111 challenging proteins from several signaling pathways) in HeLa digest using "100 samples/day" LC method.



CONCLUSIONS

- The developed fast LC-PRM set-ups exhibited the ability to quantify with high sensitivity several dozens of endogenous peptides in one hundred samples within one day under high efficiency acquisition modes.
- Advanced PRM methods combined with multiplexed immunoprecipitation increased the throughput of signaling pathway monitoring without compromising data quality. The novel single-scan IS-PRM msx method turned out to be an attractive option for broad-coverage/multi-pathway monitoring studies, which however needs to be further investigated.

REFERENCES

- Gallien S, Kim SY, and Domon B; Mol. Cell. Proteomics, 2015
- Thoeing S, Gallien S, Arrey T, Xuan Y, Lange O, Strupat K, and Kellmann M, PO-64997, Thermo Fisher Scientific, 2017

TRADEMARKS/LICENSING

© 2018 Thermo Fisher Scientific Inc. All rights reserved. Evosep and EvoTips are trademarks of Evosep. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. This information is not intended to encourage use of these products in any manner that might infringe the intellectual property rights of others. PO65232-EN 05185

ThermoFisher
SCIENTIFIC